Founded in 2014, Kono Chem Co., Ltd is an export-oriented production enterprise supported by the State Department of Commerce.
Kono Chem covers an area of 312,000 square meters, with scientific and technological personnel accounting for more than 35%. The headquarter of the company is located in Xi'an, Shaanxi Province. It consists of two chemical fermentation workshops, a pilot-scale reaction workshop and a provincial R&D center. Since the establishment of the company, it has been recognized by customers at home and abroad and audited by authoritative laboratories in accordance with ISO9000, ISO14001 and specifications. At present, the company's main products involve biopharmaceuticals, flavors and fragrances, pesticide intermediates, veterinary drug development, and some custom synthesis.

With comprehensive EHS management and high-quality advantages, Kono Chem sells 85% of its products in more than 50 countries around the world, and has established long-term strategic partnerships with multinational companies such as CIPLA, BIOCON, and DSM. The company adheres to the business tenet of "integrity and diligence", with an efficient research and development system, simple and diligent employees, and a responsible corporate culture, and sincerely invites domestic and foreign colleagues who are willing to cooperate for a long time to join the mission for the development of the chemical raw material industry.

Dienoest is a selective progesterone drug that has been launched in recent years. It can stabilize endometrial tissue by specifically binding to ethylene nortestosterone and progesterone derivatives. Studies have found that tumor necrosis factor (TNF). and interleukin (IL-8) tend to increase in patients with endometriosis.

Dienogest is a mixed progestogen with dual properties of 19-nortestosterone derivatives and progesterone derivatives; therefore, it combines the pharmacological advantages of natural and synthetic progestins with high progestogenic activity . A large randomized, double-blind, placebo-controlled clinical trial conducted by Harada et al showed that after taking dienogest 2 mg/d for 24 weeks, it improved the symptoms of endometriosis-related lower abdominal pain, low back pain, and pain during intercourse. The curative effect is similar to buserelin, but the adverse reaction rate such as vaginal bleeding and bone mineral density decrease is significantly lower, and the tolerance is better.

Dienogest is a synthetic contraceptive drug belonging to the 19-nortestosterone class of progestogens with strong progestogenic and anti-androgenic activities. This drug reduces sperm motility by affecting sperm energy metabolism. Dinogest was successfully developed by the German company Schering and is used in oral contraception due to its strong ovulation inhibition effect. It has the characteristics of definite curative effect and less toxic and side effects, and is becoming the drug of choice for oral contraception.